Q&A Zealand Pharma 2022-03-22

	22/3 15:29 af HanneP	How quickly do you expect glepaglutid to achieve a satisfying penetration of the market once it eventually has been approved?
	22/3 15:30 af Emmanuel Dulac	We are confident that glepaglutid has a very competitive profile and could provide a much-needed alternative for patients. We are not able to give detailed market dynamics on a product that is currently not approved, but see good opportunities for capturing both existing and new patients segments with an attractive product profile.
	22/3 15:30 af collersteen	On the BI-partnership. I know Zealand won't guide on potential revenue from existing license agreement, but should we expect anything from the current ongong phase 2 studies? Or would it be more likely to see income from the Alexion-partnership?
	22/3 15:31 af Emmanuel Dulac	Both partnerships are progressing well, and we look forward to updating on progress in the future.
	22/3 15:32 af collersteen	Alexion/AZN: Have you noticed any change in the nature of partnership, now that AZN has been in charge for almost a year?
	22/3 15:34 af Emmanuel Dulac	This has always been a very good partnership and we are encouraged by the progress being made, also since AstraZeneca acquired Alexion.
	22/3 15:34 af collersteen	Any view/update on the CHI competitive landscape? FDA has granted breakthrough therapy designation to a competing drug.
	22/3 15:35 af Emmanuel Dulac	We have not seen a change in the competitor landscape for CHI and believe that dasigucagon addresses a significant unmet medical need. We are looking forward to the pivotal Phase 3 data readout in the second quarter of this year, and if positive we would work rapidly to pursue an NDA submission with the FDA.
	22/3 15:36 af B.Andersen	Hi Emmanuel Dulac, Welcome back. Is the transformation towards the sale of own products satisfactory for you in light of the large costs associated with this in DK and US. What challenges have been the biggest in this regard?
	22/3 15:38 af Emmanuel Dulac	Thank you, it's really good to be here and have this dialogue! Like many other businesses we have been challenged by the corona pandemic which has impacted our sales. The team has worked hard to overcome the challenges they have faced, and we look forward seeing the impact on – for example - payer access during 2022. We will continue to optimize our operating model to also secure success of potential future launches.
	22/3 15:38 af B.Andersen	Relating to obesity and the cooperation with Boehringer Ingelheim - how do the drugs from Zealand Pharma differ from the drug Novo and Lilly have?
	22/3 15:40 af Emmanuel Dulac	Good that Adam is here as he is an expert on this. BI456906 is a dual-acting peptide that stimulates both the GLP-1 receptor (like Novo’s semaglutide) and the glucagon receptor, which is a novel approach. The hypothesis behind stimulating both receptors are to achieve the beneficial effect of GLP1 on glucose, appetite etc and the effect of glucagon on energy expenditure thereby potentially achieving higher weight loss...
	22/3 15:42 af Emmanuel Dulac	Lilly’s terzipitide is stimulating the GLP1 and GIP receptors and thus target somewhat different biology.
	22/3 15:42 af Helge Larsen/PI-redaktør	Question fra Exitnu; Dutch Van Herk Investment is a major shareholder in  Zealand Pharma. Van Herk Investments has done a remarkable job with their long-term investment strategy. Investing in many different and exciting biotech companies throughout the years and has continued doing so in 2021 and 2022. Do you see Van Herk Investments as an obvious candidate for a possible private placement in the future?
	22/3 15:43 af Emmanuel Dulac	We are very happy to have Van Herk as a significant investor in Zealand. However, we cannot comment on future financing or individual investors....
	22/3 15:45 af Emmanuel Dulac	We have a strong financial position going into 2022, with a cash position of 1.4 billion DKK and in the light of the current situation in the financial markets, we are also very glad to have secured non-dilutive financing with the loan agreement with Oberland Capital which supports the financing of our pipeline going forward.
	22/3 15:45 af Helge Larsen/PI-redaktør	The last question is from Exitnu: When will we be returning to physical general meetings? Personally it has been a great pleasure being able to meet and talk “across the coffee table” at Plesner with e.g.(/for an example) an Advisory Board member and others who can add new perspectives.
	22/3 15:46 af Emmanuel Dulac	We very much enjoy the opportunity to meet with our shareholders face to face at the Annual General Meeting (AGM). Virtual meetings are, however, a good alternative to provide access to the company for those who cannot join meetings in person.….
	22/3 15:47 af Emmanuel Dulac	We also need to balance the advantages of holding a physical meeting with the need to follow healthcare advice and protect the well-being of our employees, shareholders, and other stakeholders. This year our AGM will be held virtually, but we will continue to evaluate the right form for the AGM going forward.
	22/3 15:47 af Helge Larsen/PI-redaktør	Emmanuel Dulac and Adam Steensberg ..Thank You for joining us and thank you for the many fulfilling answers to our questions. We look forward to to seeing you back here on ProInvestor.com after Q1.
	22/3 15:48 af Emmanuel Dulac	It has been a real pleasure, thank you - we look forward to meeting you again soon.
	22/3 15:50 af Helge Larsen/PI-redaktør	This session is endet. :-)